Discover open access scientific publications

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein Gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group